SDHAF2相关家族性副神经节瘤综合征临床特征的新见解
研究前瞻性评估56例携带SDHAF2基因p.(Gly78Arg)变异的个体,其中33例发生副神经节瘤/嗜铬细胞瘤。肿瘤均呈父系遗传,多数为头颈部副神经节瘤且多灶性常见,[68Ga]Ga-DOTA-TOC PET/CT对多灶性病变和转移灶的检出率高于[18F]DOPA PET/CT。
要点
- 33例(58.9%)发生SDHAF2相关肿瘤,诊断平均年龄38.6±17.2岁,肿瘤均为父系遗传。
- 26例(78.8%)为多灶性病变,16例(48.5%)诊断时无症状,2例(6.1%)出现转移性疾病。
- [68Ga]Ga-DOTA-TOC PET/CT对多灶性副神经节瘤和转移灶检出率为95.7%,高于[18F]DOPA PET/CT的79.3%。
核心结论
- 本研究为SDHAF2相关副神经节瘤综合征的表型特征提供新见解,包括颈外副神经节瘤的发生和转移性转化。
研究设计与样本
- 前瞻性评估56例携带SDHAF2基因p.(Gly78Arg)变异的个体,收集其中33例发生副神经节瘤/嗜铬细胞瘤者的临床、生化及影像数据。
- 对22例副神经节瘤/嗜铬细胞瘤患者行[68Ga]Ga-DOTA-TOC与[18F]DOPA PET/CT以比较准确性,并对13例手术标本行显微镜评估。
主要发现
- 33例(58.9%)发生SDHAF2相关肿瘤,其中17例(51.5%)为女性,诊断平均年龄38.6±17.2岁,肿瘤均为父系遗传。
- 除1例外所有评估患者均表现为头颈部副神经节瘤,11例(33.3%)有纵隔和腹部肾上腺外副神经节瘤,2例有嗜铬细胞瘤。
- 26例(78.8%)为多灶性,16例(48.5%)诊断时无症状,仅4例副神经节瘤/嗜铬细胞瘤患者有去甲变肾上腺素或3-甲氧酪胺分泌。
- 2例(6.1%)观察到转移性疾病;肾上腺嗜铬细胞瘤和副神经节瘤分级系统评分≥3者占肿瘤的84.6%,肾上腺嗜铬细胞瘤分级量表评分≥4者占69.2%。
- [68Ga]Ga-DOTA-TOC PET/CT对多灶性副神经节瘤和转移灶的检出率为95.7%,高于[18F]DOPA PET/CT的79.3%,且平均最大标准化摄取值更高。
关键数值与推荐
- [68Ga]Ga-DOTA-TOC PET/CT对多灶性副神经节瘤和转移灶检出率95.7%,[18F]DOPA PET/CT为79.3%。
- 肾上腺嗜铬细胞瘤和副神经节瘤分级系统评分≥3者占肿瘤的84.6%,肾上腺嗜铬细胞瘤分级量表评分≥4者占69.2%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The clinical characterization of SDHAF2-related familial paraganglioma syndrome remains elusive. The aim of this study is to contribute to the knowledge of this syndrome with valuable new information. METHODS: A total of 56 individuals with the p.(Gly78Arg) variant in the SDHAF2 gene were prospectively evaluated. Of the 33 subjects who developed paragangliomas (PGLs)/pheochromocytomas (PCs) throughout follow-up, clinical, biochemical, and imaging data were collected. [68Ga]Ga-DOTA-TOC and [18F]DOPA positron emission tomography/computed tomography (PET/CT) scans were carried out on a subset of 22 patients with PGLs/PCs to compare their accuracy; surgical specimens (n = 13) were microscopically evaluated to elucidate their potential malignant behavior. RESULTS: Of the 33 patients (58.9%) with SDHAF2-related tumors, 17 (51.5%) were women, with a mean age at diagnosis of 38.6 ± 17.2 years. Tumor development was found to be inherited paternally in all subjects. All the patients evaluated except 1 showed head and neck PGLs. Eleven patients (33.3%) showed mediastinal and abdominal extra-adrenal PGLs and 2 patients presented PCs. Multifocality was observed in 26 subjects (78.8%). Sixteen patients (48.5%) were asymptomatic at diagnosis. Only 4 patients with PGLs/PCs showed normetanephrine or 3-methoxytyramine secretion. Metastatic disease was observed in 2 patients (6.1%). Grading System for Adrenal Pheochromocytoma and Paraganglioma score was ≥3 in 84.6% of tumors and Pheochromocytoma of the Adrenal Gland Scaled Score was ≥4 in 69.2%. [68Ga]Ga-DOTA-TOC PET/CT showed a greater detection rate (95.7%) of multifocal PGLs and metastatic lesions than [18F]DOPA PET/CT (79.3%), as well as higher mean maximum standardized uptake value. CONCLUSION: The current study offers new insights into the phenotypic characterization of SDHAF2-related paraganglioma syndrome including the development of extra-cervical PGLs and metastatic transformation.
引用
- Fernandez-Pombo A, Nogareda-Seoane Z, Cameselle-Teijeiro JM, et al. New Insights into the Clinical Characterization of SDHAF2-related Familial Paraganglioma Syndrome. J Clin Endocrinol Metab. 2025. PMID: 40079348. doi:10.1210/clinem/dgaf149
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。